Pantoprazole occurs as proton pump inhibitor drug used for short-short-run coarse of action of erosion & ulceration of the oesophagus from either gastroesophageal reflux disease. Initial coarse of action is typically of eight weeks' duration, when which some other eight week course of coarse of action can be considered in case necessary.

Pantoprazole was developed by Altana and is currently marketed under a marque Protonix® by Wyeth-Ayerst Laboratories, Somac® by Pfizer, and when Pantoloc® by [http://www.solvaypharma.ca/ Solvay Pharma]. These are available by guide inside controlled-release tablets.